Creative Medical Technology Holdings, Inc.: Form 10-Q for the period ended Mar 31, 2019
Filed with the SEC on May 20, 2019 and accepted by EDGAR at May 20, 2019, 16:46 ET.
Management's discussion and analysis
As filed, 13,524 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Management’s Discussion and Analysis of Financial Condition and Results of Operations analyzes the major elements of our balance sheets and statements of income. This section should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2018, and our interim financial statements and accompanying notes to these financial statements included in this report. All amounts are in U.S. dollars.
Forward-Looking Statement Notice
This quarterly report on Form 10-Q contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by us with the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, those set forth in our most recent annual report referenced below.
This report identifies important factors which could cause our actual results to differ materially from those indicated by the forward-looking statements.
All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.
Overview
We are considered to be a commercial stage company, following the commencement of sales of disposable stem cell separation kits used in our Caverstem® procedure to treat ED in the fourth quarter of 2017. In the fourth quarter of 2018 we initiated sales of disposable stem cell separation kits in our FemCelz™ procedure to treat female sexual disfunction. Our fiscal year end is December 31st. We have acquired the licensing rights for our Amniostem amniotic-based stem cell, purchased the patent for our ED and lower back pain treatments, and filed patent applications for our neurological treatments.
During the first three-months of 2019, we issued $672,100 in convertible notes with net proceeds of $605,300 to accredited investors. In addition, we issued $300,000 in convertible notes for the extinguishment of 9,698,736 warrants.
During the three-month period ending March 31, 2019, we incurred interest expense of $454,542 arising from the third-party notes of $2,092,225.
Plan of Operations
We commenced marketing disposable stem cell separation kits for the Caverstem® ED treatment in the fourth quarter of 2017. We commenced marketing disposable stem cell separation kits for the FemCelz™ procedure to treat female sexual disfunction in the fourth quarter of 2018. For the next 12 months our plan of operations is to market our disposable kits, publish the results of the UCLA/LABiomed clinical trial and partner with leading researchers on investigator-initiated trials to advance our neurological programs. As of March 31, 2019, we had approximately $419,477 cash on hand. With an estimated monthly cash burn rate of approximately $100,000 based on historic trends and anticipated future revenues and expenses, management anticipates sufficient cash on hand and committed funds to meet operating expenses and costs of the current operations through at least June 2019. Historically, we have met our cash flow requirements through the sale of equity securities or borrowed funds. We intend to fund our business through sales of disposable kits along with continuing to seek investments to meet our cash flow requirements, including both operating expenses and the balance of funding required to fund our sales efforts and compete our ED clinical trial. The securities offered by us to potential investors have not been registered under the Securities Act of 1933, as amended (the “Act”), and may not be offered or sold in the U.S. absent registration or an applicable exemption from registration requirements. If we are unable to obtain further financing, we may seek alternative sources of funding or revise our business plan. We currently have no alternative sources for funding.
Results of Operations – For the Three-month Period Ended March 31, 2019 and 2018
Gross Revenue. We generated $50,800 gross revenue for the three-month period ended March 31, 2019 in comparison with $9,600 for the comparable quarter a year ago. The increase of $41,200, or 429% is due to the continued commercialization of the Caverstem® procedure.
Cost of Goods Sold. We generated $14,239 cost of goods sold for the three-month period ended March 31, 2019 in comparison with $2,400 for the comparable quarter a year ago. The increase of $11,839, or 493% is due to the increased sales associated with the continued commercialization of the Caverstem® procedure.
Gross Profit/(Loss). We generated $36,561 in gross profit for the three-month period ended March 31, 2019 in comparison with $7,200 for the comparable quarter a year ago. The increase of $29,361, or 408% is due to the increased sales associated with the continued commercialization of the Caverstem® procedure.
General and Administrative Expenses. General and administrative expenses for the three-month period ended March 31, 2019, totaled $281,974, in comparison with $202,930, for the comparable quarter a year ago. The increase of $79,044, or 39% is primarily due increased marketing expenses associated with the Caverstem® procedure commercialization, physician training, and legal and accounting fees associated with debt issuances and public company reporting.
Research and Development Expenses. Research and development expenses for the three-month period ended March 31, 2019, totaled $0 in comparison with $3,200, for the comparable quarter a year ago. The decrease of $3,600, or 100% is due to the completion of clinical activities associated with the erectile dysfunction trial and pre-clinical research on the Anmiostem stem cell.
Other Income / Expense. Other expense for the three-month period ended March 31, 2019, totaled $546,667 in comparison with other expense of $7,382,364, for the comparable quarter a year ago. The decrease of $6,835,697, or 92% is primarily due to a decrease of $7,301,939 in the change in the fair value of derivative liabilities, offset by an increase of $263,234 in interest expense.
Net Loss. For the reasons stated above, our net loss for the three-month period ended March 31, 2019 totaled $797,366 in comparison to $7,586,580, for the comparable quarter a year ago.
Liquidity and Capital Resources
Our principal source of liquidity has been funds received from the sale of our common stock and issuance of notes including convertible notes. Our experience to-date indicates the lenders are most likely to convert the debt into equity prior to or in lieu of full payment at maturity. Going forward, our short-term funding needs are expected to be satisfied by funds to be loaned to us by third parties and revenues generated from our Caverstem® ED and FemCelz™ female sexual dysfunction procedures. Our long-term liquidity needs are expected to be satisfied from future offerings of our equity securities. It is possible that CMH may provide future financing for us. We do not have any arrangements, agreements, or sources for long-term funding.
Our only commitments for expenditures relate to the completion of the clinical study for the ED stem cell treatment and general and administrative costs, including reimbursements to our parent company for services performed by their executive officers on our behalf. During the next 12 months we also anticipate incurring expenses related to marketing activities for our ED treatment.
For the next 12 months our plan of operations is to market disposable kits associated with the Caverstem® ED and FemCelz™ female sexual dysfunction treatments and publish the UCLA/LABiomed clinical trial. We believe that our current cash on hand would meet our cash flow requirements for only a few more months. If we are unable to obtain further financing, we may seek alternative sources of funding or revise our business plan. We currently have no alternative sources for funding.
Our financial statements included with this report have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have incurred substantial expenses and generated minimal revenues from operations during the periods covered by these financial statements. These factors raise substantial doubt about our ability to continue as a going concern. There is no assurance that we will be successful in meeting the continuing financial obligations of the company. Our financial statements do not include any adjustments that might result from the outcome of these uncertainties.
Cash Flows
Net Cash used in Operating Activities. We used cash in our operating activities due to our losses from operations. Net cash used in operating activities was $273,015 for the three-month period ended March 31, 2019 in comparison to $164,937 for the comparable period a year ago, an increase of $108,078 or 66%. The increase in cash used in operations was primarily related to payments towards an outstanding balance of management fees payable to a related party.
Net Cash used in Investing Activities. There was no cash used in investing activities in the three-month period ended March 31, 2019 and the comparable period a year ago.
Net Cash From Financing Activities. In the three-month period ended March 31, 2019 we raised $575,890 through the issuance of convertible debt in comparison to $254,350 for the comparable period a year ago. In the three-month period ended March 31, 2019 we paid $168,300 to extinguish an outstanding convertible note to a third party. The increase in cash flows from financing activities was primarily related to our need to obtain additional capital due marketing expenses associated with the commercialization of the Caverstem® ED and FemCelz™ female sexual dysfunction procedures, increases in capital markets marketing costs and increased legal and accounting fees associated with public company reporting and audit requirements.
Basis of Presentation / Going Concern
The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of March 31, 2019, the Company had $419,477 of available cash and a working capital deficit of $3,762,999. For the three-month period ended March 31, 2019, the Company had $50,800 in revenue, $36,561 in operating income and used net cash for operating activities of $273,015. These factors, among others, indicate that the Company may be unable to continue as a going concern for the next twelve months. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing as may be required, and ultimately to attain sufficient cash flow from operations to meet its obligations on a timely basis. Management is in the process of negotiating various financing plans including access to ongoing credit facilities and possible sale of capital stock either in private or in public offerings and believes these steps may generate sufficient cash flow for the Company to continue as a going concern. If the Company is unsuccessful in these efforts, it may be required to substantially curtail or terminate its operations.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our consolidated financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity capital expenditures or capital resources.
Controls and procedures
As filed, 1,418 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of disclosure controls and procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13(a)-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report are effective in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Changes in internal control over financial reporting
There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-01-01 to 2019-03-31 | $50.8k | us-gaap:Revenues |
| Cost of revenue | 3 months2019-01-01 to 2019-03-31 | $14.2k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2019-01-01 to 2019-03-31 | $36.6k | us-gaap:GrossProfit |
| Research and development | 3 months2019-01-01 to 2019-03-31 | $0 | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-01-01 to 2019-03-31 | −$250.7k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-01-01 to 2019-03-31 | $454.5k | us-gaap:InterestExpense |
| Income tax | 3 months2019-01-01 to 2019-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-01-01 to 2019-03-31 | −$797.4k | us-gaap:NetIncomeLoss |
| Operating cash flow | 3 months2019-01-01 to 2019-03-31 | −$273.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2019-03-31 | $419.5k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-03-31 | $419.6k | us-gaap:AssetsCurrent |
| Total assets | At period end2019-03-31 | $577.9k | us-gaap:Assets |
| Current liabilities | At period end2019-03-31 | $4.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-03-31 | $4.2m | us-gaap:Liabilities |
| Long-term debt | At period end2019-03-31 | $2.0m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2019-03-31 | −$3.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001144204-19-027322. Last ingested by Listed: Nov 14, 2026, 19:08 ET. Listed shows no prices and gives no investment advice.